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Abstract
Purpose - It is conceivable that cannabis cultivators who grow for medical purposes aim to improve the 
therapeutic index oftheir cannabis byattempting to produce particular concentrations ofCBD and/or THC. The 
purpose ofthis paper is to examine whether small-scale medical cannabis growers differfrom those growing for 
recreational reasons in terms of self-assessed concentrations of THC and CBD in the cannabis they grow. 
Design/methodology/approach - Data collection was conducted Online from a convenience sample of 
268 cannabis growers visiting a popular Israëli cannabis internet forum. / and KruskaHWallis H were used to 
test bivariate associations between medical and recreational cannabis cultivators in terms of self-assessed 
cannabinoid concentrations.
Findings - In totai, 40 percent of cannabis growers reported that they grow for medical purposes. Medical 
cannabis growers were more likely to report that they thought they knew the cannabinoid concentrations of 
the cannabis they grew and they reported higher self-assessed concentrations of THC, but not CBD. 
Originality/value - Compared to recreational growers, medical cannabis growers are more likely to strive to 
fee informed in terms of the content oftheir cannabis. Medical growers may also fee attempting to grow more 
potent THC but not CBD cannabis.
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Introduction
Cannabis is the most widely used controlled drug in the world. While most commonly used for 
recreational purposes (e.g. to get high, socialise), cannabis is increasingly being recognized and 
used as a remedy for various medical symptoms and conditions (The National Academies of 
Sciences, Engineering, and Medicine, 2017). Cannabis contains numerous cannabinoids, but 
A9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are typically the most concentrated 
components (Russo, 2011). THC is usually the most prevalent psychoactive constituent, 
producing the “high” associated with cannabis use. THC can also induce anxiety, psychotic-like 
experiences and cognitive impairment (Colizzi and Bhattacharyya, 2017). At the same time, 
research shows that THC possesses immunosuppressive and neuroprotective properties 
(Jamontt et al., 2010). Furthermore, research suggests that CBD has neuroprotective, 
anti-inflammatory and anti-oxidative properties (Campbell and Gowran, 2007; Cheng et al., 
2014) and that it may attenuate the psychotic-like effects of THC (Russo, 2011).
Small-scale (non-commercial) domestic cannabis cultivation has grown rapidly in Europe 
and North America over recent years (Chadillon-Farinacci et al., 2015; Potter et al., 2015; 
Davenport and Caulkins, 2016). Yet, small-scale growing is likely to supply only a modest share
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of the overall cannabis market, especially in jurisdictions that have legalised cannabis which, in 
turn, is associated with increases in large-scale cannabis cultivation and “professionalisation” of 
the cannabis market (Davenport and Caulkins, 2016). Furthermore, research has found that 
people who report that they grow cannabis to provide themselves or others with cannabis tor 
medical purposes (henceforth “medical cannabis cultivators”) represent a substantial proportion 
of small-scale cannabis growers (Hakkarainen et al., 2015, 2017).
It is possible that “medical cannabis cultivators” differfrom “recreational cannabis cultivators” in 
terms of the self-assessed THC and CBD concentrations in the cannabis they grow because of a 
desire to achieve a selective breed of cannabis that is thought to improve the therapeutic index. 
Because THC is the main psychoactive ingrediënt and because medical users may not seek the 
psychoactive effects of cannabis, medical cultivators may attempt to achieve lower levels of THC 
than recreational growers. Indeed, there is some evidence that medical cannabis patients prefer 
lower THC cannabis because it treats their symptoms without the accompanying psychoactive 
highs (Harris et al., 2000). Nevertheless, THC is known to have therapeutic effects and thus there 
is also reason to expect that medical growers may not attempt to produce lower THC 
concentrated cannabis than recreational growers. Since CBD is known to have therapeutic 
effects, but no psychoactive effects, medical cannabis cultivators may be more likely than 
recreational cannabis cultivators to attempt growing high CBD cannabis, it is also possible that 
the differences between growers lie in the CBD:THC ratio that due to the potential therapeutic 
benefits of both THC and CBD medical cannabis growers may be more likely to attempt a 
relatively balanced CBD:THC ratio.
The aim of this study is to expand the knowledge on medical cannabis cultivators by examining 
whether small-scale medical cannabis growers differ from those growing for recreational reasons 
in terms of self-assessed concentrations of THC and CBD in the cannabis they grow. The sample 
consists of small-scale cannabis growers in Israël. Israël is an interesting case study for 
the current project as it is the home of an established medical cannabis programme. Indeed, the Israëli 
Ministry of Health has been running a cannabis program since the 1990s and there are (as of 2017) 
approximately 28,000 licensed medical cannabis patients in Israël (Zarhin et al., 2018; Tandowski 
et al. ,2019). There are eight private growers who legally supply these patients with medical cannabis. 
Israëli cannabis policies do not allow for home growing for medical or recreational purposes. 
Nevertheless, unlicensed medical cannabis use has been reported (Sznitman, 2017; Tandowski et al., 
2019) and the current study focuses on a sample of cannabis cultivators who grow cannabis illegally.
Methods
Data for this study stem from the Israëli version of the International Cannabis Cultivation Questionnaire 
developed by the Global Cannabis Cultivation Research Consortium (GCCRC) to measure patterns 
of small-scale cannabis cultivation (Decorte et al., 2012). The methods and data of the GCCRC study 
have been described in depth elsewhere (Barratt et al., 2015). The current study is based on Israëli 
cannabis growers who reported cultivating within the last five years. Respondents were recruited 
through the Israëli Cannabis Magazine, a popular cannabis internet forum in Israël. A link to the online 
questionnaire was placed on the website and the forum moderator encouraged users to participate 
through social media. After informed consent was provided and inclusion criteria fulfilled (age > 17), 
respondents completed the anonymous survey. The study was approved by the Institutional Review 
Board of the Faculty of Social Welfare and Health Sciences at the University of Haifa.
Variables
Medical vs recreational growers. Medical vs recreational growers was measured by asking the 
respondents whether or not they grow in order to “provide others with cannabis for medical 
reasons” or “provide myself with cannabis for medical reasons.” In total, 13 respondents reported 
growing to provide others with cannabis for medical reasons, 73 reported growing to provide 
themselves with cannabis for medical reasons and 13 other respondents reported in the affirmative 
to both questions. Sub-group analyses were not feasible due to insufficiënt cases in each category. 
Therefore, affirmative responses to any of these questions were coded as medical cannabis growers 
( = 1), otherwise respondents were coded as recreational growers (= 0).
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Cannabis concentrations. Respondents were coded in terms of whether they reported that they 
knew the concentrations of the cannabis they grow (0 = no, 1 = yes). Those who answered in the 
affirmative were subsequently asked how they know the concentrations (by relying on source of 
seeds/cuttings; relying on feeling/experience; by measuring with a kit/laboratory) and to report, to 
the best of their knowledge, the average THC and CBD concentration in the cannabis they grow. 
We also calculated the THC:CBD ratio.
Sociodemographic variables. Sex (0 = female, 1 = male), age (18-74), whether respondents had 
a university degree (0 = no, 1 =yes) and worked full time (0 = no, 1 =yes) were recorded.
Statistical models
Bivariate associations between medical and recreational cannabis cultivators and demographic 
background and cannabis concentrations were assessed using^2 tests for categorical variables 
and Kruskal-Wallis H test (due to non-normal distributed data) for continuous variables. Statistical 
analyses were conducted with SPSS Ine. (2010).
Results
Almost all respondents were male (95 percent), the mean age was 28 years (SD = 8.58), 32 percent of 
the sample had a university degree and 47 percent reported working full time (Table I). Overall 
40 percent of cannabis growers reported that they grow for medical purposes. There was no signfficant 
difference between medical and recreational cannabis growers in terms of gender or average age 
(p > 0.05). However, medical cannabis growers were less likely to have a university degree (25 vs 37 
percent, p=0.038) and less likely to be working full time (34 vs 54 percent, p = 0.001).
Medical cannabis growers were more likely to report that they thought that they knew the 
concentrations of the cannabis they grew compared to recreational cannabis growers (72 vs 
57 percent, p = 0.006). When conducting further analyses on the sub-sample that reported knowledge 
of cannabis concentrations (n = 167, Table II), results showed no differences in terms of methods 
used to test the concentrations. The most commonly reported source of knowledge was relying on 
source seeds/cuttings (75 percent) while very few (4 percent) reported relying on a kit/laboratory.
A large range of estimated cannabinoid concentrations was reported (THC: 3-42 percent; CBD: 
0-44 percent). While there was no difference between medical and recreational growers in terms 
of assessed CBD concentration and THC:CBD ratio (p>0.05), medical cannabis growers 
reported higher THC concentrations compared to recreational cannabis growers (mean = 20 
vs 17 percent, p = 0.026).
THC and CBD concentrations as high as those reported by some of the respondents seem highly 
unlikely. For instance, in a recent report from the Netherlands, it was found that the highest THC 
cannabis content products on the market were 27 percent (Rigter and Niesink, 2017), whereas a 
few respondents in the current sample reported up to 42 percent THC. To test whether there 
were group differences once very extreme estimates were excluded, we tested mean differences 
again, this time excluding respondents reporting THC > 27 percent. Once these outliers were
Table I Sample characteristics and bivariate associations between medical and recreational growers
Recreational cannabis growers Medical cannabis growers
Total (n=268) (n = 769, 63.7%) (n = 99, 39.6%) Statistical test
Sociodemographic background
/(1 ) = 3.549, p = 0.058Male, n (%) 255 (95.1) 164(97.0) 91 (91.9)
Age, mean (SD) 28.02 (8.58) 27.91 (7.98) 28.21 (9.55) /(1) = 0.324,p = 0.569
University degree, n (%) 86 (32.3) 61 (36.5) 25 (25.3) /(1 ) = 3.611,p = 0.038
Work full time, n (%) 125(46.6) 91 (53.8) 34 (34.3) /(1 ) = 9.541, p = 0.001
Cannabis growing
Know potency, n (%) 167(62.5) 96 (56.8) 71 (72.4) /(1 ) = 6.953, p = 0.006
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Recreational cannabis Medical cannabis 
Total (n = 167) growers (n = 96, 57.5%) growers (n = 71, 42.4%) Statistica! test
Know by relying on source seeds/cuttings, n (%) 
Know by relying on feeling/experience, n (%) 
Know by measuring with a kit/laboratory, n (%) 
% THC, mean (SD)
% CBD, mean (SD)
THC:CBD
124 (75) 
34 (20.6) 
7 (4.2)
73 (77.7) 
19(20.2) 
2(2.1)
51(71.8) /(I) = 2.502, p = 0.286
15(21.1)
5 (7.0)
18.31 (6.19) 
5.08 (6.43) 
8.79(7.17)
17.30(5.02) 
5.38 (6.38) 
9.64 (7.32)
19.63(7.28) /2(1) = 4.986, p = 0.026
4.74(6.51) /(1) = 0.101,p = 0.751
8.00(6.99) /(1 ) = 0.483, p = 0.48^
Notes: THC, delta-9-tetrahydrocannabinol; CBD, cannabidiol
excluded there was no mean difference in assessed THC levels between recreational anc 
medical cannabis growers; also, the exclusion did not change the insignificant mean difference! 
found for the full sample for CBD and THC:CBD ratio.
Discussion
The current study shows that in this sample of Israëli cannabis cultivators, there is a relatively larg< 
proportion of cultivators who grow for medical reasons. The results are consistent with those from I 
separate Israëli sample of cannabis users, which found that 38 percent use cannabis for medici 
reasons (Sznitman, 2017), and an international study of small-scale cannabis growers, whici 
showed that 45 percent grow for medical purposes (Hakkarainen et al., 2017). It is, however 
important to point out that the current study was conducted in a self-selected sample of visitors o 
an online discussion forum which limits the ability to assess its representativeness of cannabii 
growers in Israël. This method was, however, chosen because it provides ease of access, broai; 
reach, anonymity and reduced response bias on sensitive topics (Ramo et al., 2012).
Results reported here further show that medical cannabis growers were more likely to report thal 
they thought they knew the concentrations of the cannabis they grow. This suggests that medicej 
growers may have more interest in knowing the concentrations, potentially because they aim t< 
improve the therapeutic index of their cannabis. Medical cannabis growers also reported highe 
self-assessed THC concentrations but not higher CBD concentrations which run counter to tb 
expectation that medical cannabis users try to avoid or minimiss the psychoactive effects of cannabii 
(Harris et al., 2000). Yet, unpublished data from Israël show that medical cannabis licensed chronii 
pain patients in Israël tend to use high THC cannabis (Meiri, 2019). One of the questions that th 
raises is that respondents may define themselves as medical growers as a strategy to minimis 
stigma and legitimise their growing and using practices, whereas the boundary between medical ant 
recreational use is actually quite blurred (Hakkarainen et al., 2017). More research on how and whj 
some growers define themselves as medical growers is needed to explore this further.
The extent to which the self-reported concentration levels are correct is not possiblj 
to determine with the current data. Indeed, there is a potential discrepancy betweer 
self-assessments and actual concentrations of the cannabis produced, especialiy since ven 
few cultivators reported that they base their concentration assessment on kit/laboratoij 
testing. Furthermore, studies based on legally produced cannabis show discrepancie 
between actual THC and CBD content and the THC and CBD content reported on cannabii 
packaging (Vandrey et al., 2015; Bonn-Miller et al., 2017), indicating that even in legal marketi 
the ability or willingness to objectively and correctly test THC and CBD content is limited 
There is therefore reason to believe that there are discrepancies between the self-assessec 
THC and CBD levels reported by our respondents and objectively measured levels. Th< 
current results suggest that medical cannabis growers may be particularly prone to ovef 
estimate the THC levels of their cannabis. Indeed, in sensitivity analyses excluding extremel; 
high self-assessed THC estimates results failed to replicate the full sample result that medio 
cannabis cultivators report higher mean THC. Future research with objectively lab testec 
cannabinoid concentrations is needed to better understand the validity of self-reportef 
cannabinoid concentrations among small-scale growers.
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As opposed to interpreting the results of the THC/CBD self-assessments as objective indicators 
of cannabis concentrations produced by respondents in this sample, the assessments may be 
interpreted as growers’ general aspirations and expectations in terms of the concentrations of 
the cannabis they grow. In this regard it is somewhat surprising that medical growers did not 
report higher CBD levels than recreational growers, seeing that CBD has no psychoactive 
effects but is known for its therapeutic effects. The results may be seen as an indication that 
medical growers are unaware of the therapeutic effects of CBD. It could also be the case 
that while they think that CBD is therapeutically beneficial, small/moderate dosages are 
seen as preferable. Considering the lack of research in this area there may be a need 
to conduct qualitative research in order to better understand the associations found in the 
current study.
The results presented in this paper show that medical cannabis growers may be particularly likely 
to aspire to improve the quality of their cannabis which suggests that they may be interested in 
reliable Information and advice on what concentrations are suited to what conditions, and on how 
to produce cannabis with the most beneficial concentrations orTHC:CBD ratio. At present, there 
is not enough research to inform the development of such guidelines. More research is needed 
that can provide safety guidelines for the use of different cannabis concentrations, how to achieve 
these levels and how to test for it.
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